Innate Pharma

Regulatory Filings • Apr 7, 2010

INNATE PHARMA UPDATES ON ITS NEXT MEETINGS WITH ANALYSTS AND INVESTORS

Marseilles, France, April 7, 2010

Innate Pharma (the "Company" - Euronext Paris: FR0010331421 – IPH) today announces its participation to the following analyst and investor conferences in the coming weeks:

• CF&B Smallcap Event, April 12-13, 2010, in Paris, France: Innate Pharma will meet with French investors specialized in small and midcap companies;
• BioEquity Europe, May 19-20, 2010, in Zurich, Switzerland: Hervé Brailly, CEO of Innate Pharma, will present the Company to European investors specialized in the biotech and healthcare sectors.

Innate Pharma is committed to meet on a regular basis with the financial community. Investors can also find updated information on the company's website (www.innatepharma.com) and contact the investor relations team by writing to investors@innatepharma.com.

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases. The Company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006. The Company has two drug candidates currently in Phase II clinical trials. Two of its preclinical programs are out-licensed to Novo Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 80 employees as at December 31, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

Disclaimer:

This press release contains information on the markets on which the Company operates and forward-looking statements. Although the Company believes this information and these expectations are based on reasonable assumptions, this information and these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (www.amf-france.org) or on Innate Pharma's website (www.innatepharma.com).

For additional information, please contact:

Laure-Hélène Mercier, Director, Investor Relations Phone: +33 (0)4 30 30 30 87 Mobile: +33 (0)6 64 18 99 59 investors@innate-pharma.fr caroline@alizerp.com

Innate Pharma Alize Public Relations

Caroline Carmagnol Phone: +33 (0)1 42 68 86 40